Lutz Hilbrich Appointed as Senator to the Senate of Economy Europe
BERLIN, Germany, March 07, 2022 / B3C newswire / -- MiGenTra and ProBioGen announce the appointment of Dr. Lutz Hilbrich, Chief Executive Officer of both companies, as Senator to the Senate of Economy Europe. The certificate of appointment was presented to Dr. Hilbrich in Strasbourg, France, today.
The Senate of Economy Europe is a Think & Do Tank. Members include representatives from business, science and society, engaged in dialogue with decision-makers from politics, business, culture and the media. The aim of the Senate is to revive the traditional idea of the senators of the antiquity on a European level: a balanced circle of independent spirit favoring the common good over self-interests. Honorary Senators like Jean Claude Juncker, Sigmar Gabriel, Klaus Töpfer, Rosi Gollmann, and in the past Hans-Dietrich Genscher, reflect the idea of what defines the Senate.
Dr. Hilbrich says: "I am truly honored by the appointment as Senator. The Senate offers the interaction on an international level with a diverse array of game changing individuals. I am particularly committed to support and drive in the Senate of Economy Europe further the idea of the Marshall Plan with Africa, where MiGenTra can play a ground-breaking role."
Caption: Dr. Lutz Hilbrich
For high resolution please click the image.
ProBioGen is a specialist in the development and manufacturing of complex therapeutic proteins.
The combination of ProBioGen's CHO.RiGHT® expression platform and state-of-the-art process development platforms, together with intelligent and innovative product-specific technologies yield biologics with optimized properties.
Rapid and integrated cell line and process development, comprehensive analytical development and robust GMP manufacturing is performed by a highly skilled and experienced team. All services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA).
ProBioGen has been operational for more than 25 years. At two locations in Berlin, more than 200 employees contribute to the creation of new therapies in medicine and groundbreaking innovations worldwide through their creative and meticulous work.
MiGenTra was founded in 2021 by ProBioGen and Minapharm Pharmaceuticals for the development and commercialization of high quality affordable biologic medicines in the field of Biosimilars, Cell- and Gene Therapies (CGT) and Vaccines to serve the needs of patients across Africa and the Middle East. MiGenTra is leveraging the strong development and manufacturing capabilities of parent companies ProBioGen and Minapharm as well as on the excellent market position of Minapharm in the region.
About Minapharm Group
The Minapharm group led by Chairman and CEO Dr. Wafik Bardissi comprises currently 4 companies, two of which are headquartered in Cairo, Egypt: Minapharm Pharmaceuticals and MiGenTra Egypt, and two with Headquarters in Berlin, Germany: ProBioGen and MiGenTra.
Dr. Gabriele Schneider
Chief Business Officer
+49 (0)30 3229 35 100
VP Corporate & Business Development and Licensing
+49 (0)30 5771 4380
Keywords: Politics; Stakeholder Participation; Lobbying; Commerce; Societies; Africa; France; Europe; Germany
Published by B3C newswire